Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Is the Mumps Vaccine Becoming Less Effective?Autism Now Diagnosed in 1 in Every 44 Children, CDC SaysNearly 7% of U.S. Kids Have Had a Head Injury or ConcussionAre Your Holiday Gifts on the 'Noisy Toy List'?Many Kids, Teens Think Girls Don't Care About Computer ScienceMost Parents Say Their Kids Aren't Thankful Enough: PollPandemic Curbed Kids' Efforts to Lose Excess WeightClimate Change May Not Increase Allergies in Kids With Asthma: StudyNearly 10% of Younger Kids Have Gotten First COVID Vaccine DoseAHA News: Family-Based Programs Targeting Childhood Obesity Can Be Good for Parents, TooCases of Children's Severe COVID-Linked Illness Were Worse in Second WaveFace Masks Don't Hide Emotions From Kids: StudyAdult 'Picky Eaters' on What Parents Did Right and WrongWHO, CDC Warn of Measles Threat After 22 Million Infants Miss Shots During PandemicWealthier Parents More Likely to Get COVID Vaccines for Young Kids: PollNearly 900,000 U.S. Kids Under 12 Have Gotten Their First COVID ShotNo Evidence Violent Video Games Lead to Real Violence: StudyDo Your Kids Really Need Cough & Cold Meds?AHA News: What Parents Should Know About the COVID-19 Vaccine For 5- to 11-Year-OldsFor Kids Afraid of Needles, These Tips May Help Ease COVID ShotsCDC Signs Off on Pfizer Vaccine for Younger KidsWe've Been Here Before: How Polio Vaccine Rollout Saved Millions of Young LivesVaccinations for Kids Will Be in Full Swing by Nov. 8, White House SaysFDA Approves Pfizer COVID Vaccine for Kids 5-11Attorneys General Warn About Pot Products That Look Like Halloween TreatsCDC Lowers Threshold for Lead Poisoning in Youngest KidsFDA Advisors Approve Emergency Use of Pfizer COVID Vaccine in Kids 5 to 11Moderna Says Its COVID Vaccine Works Well in Children Aged 6 to 11Pediatricians Offer Advice on Keeping Trick-or-Treaters SafeThe No. 1 Cause of Halloween Injuries: Carving the PumpkinPfizer Vaccine Prevents 91% of Symptomatic COVID in Young Children: FDAPfizer Says Lower Dose of Its COVID Vaccine Protects Younger ChildrenWhite House Announces COVID Vaccination Plan for Young KidsMany Parents Worry That Kids Fell Behind in Schooling During PandemicNew Device Might Spot 'Lazy Eye' in Kids EarlierA High-Tech Pointer to Pollutants That Trigger Asthma in KidsU.S. Pediatricians, Psychiatrists Declare 'Emergency' in Child Mental HealthState Spending on Poverty Really Pays Off for Kids: StudyTwo-Thirds of Parents of Kids Ages 5-11 Plan to Get Them Vaccinated Against COVID: PollKids Can Carry High, Infectious Levels of COVID CoronavirusBystanders Can Make the Difference for a Drowning ChildAs COVID Cases Drop, Fauci Tells Families to Enjoy HalloweenGolf Cart Injuries Keep Rising Among U.S. KidsStudy Confirms Rise in Child Abuse During COVID PandemicSocial Distancing Kept Kids From Getting Flu, RSVPfizer Seeks FDA Emergency Approval for COVID Vaccine in Younger KidsCould an App Help Kids With Severe Ear Condition Avoid Surgery?Kids With Food Allergies Are Often Targets for BulliesAs Kids Turned to Screens During Pandemic, Their Mental Health SufferedRacial Disparities Persist With Childhood Cancers
Links
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting
Child Development & Parenting: Infants (0-2)
Child Development & Parenting: Early (3-7)

Pfizer Seeks FDA Emergency Approval for COVID Vaccine in Younger Kids

HealthDay News
by Robert Preidt and Robin Foster
Updated: Oct 7th 2021

new article illustration

THURSDAY, Oct. 7, 2021 (HealthDay News) -- Pfizer Inc. announced Thursday that it has asked the U.S. Food and Drug Administration for emergency approval for its coronavirus vaccine to be given to children between the ages of 5 and 11.

"We're committed to working with the FDA with the ultimate goal of helping protect children against this serious public health threat," the company said in a tweet announcing the FDA filing.

Meanwhile, the FDA has already scheduled an Oct. 26 meeting to consider Pfizer's request, with a ruling expected between Halloween and Thanksgiving, the New York Times reported.

Pfizer has proposed giving children one-third of the adult dosage, which may require adding more diluent to each injection or using a different vial or syringe, the Times reported. Vaccine doses for children will likely require new labeling and special codes that would enable the U.S. Centers for Disease Control and Prevention to track specific vaccine lots in the event of reports of serious side effects.

If the Pfizer vaccine is authorized for these younger children, it could offer protection to an additional 28 million Americans, according to the Times.

According to the American Academy of Pediatrics, nearly 5.9 million Americans younger than 18 have been infected with the coronavirus. Of the roughly 500 Americans under 18 who have died, about 125 were children ages 5 to 11.

"It really bothers me when people say kids don't die of COVID," said Dr. Grace Lee, an associate chief medical officer at Stanford Children's Health who also leads a key advisory committee to the CDC.

"They die of COVID. It's heartbreaking," she told the Times.

People younger than 18 have accounted for about 1 in every 6 Americans infected since the start of the pandemic, but that increased to as many as 1 in 4 infections last month as the Delta variant dominated the country.

In May, the FDA granted emergency use of the Pfizer vaccine in 12- to 15-year-olds.

The FDA's review of a Pfizer dose for children ages 5 to 11 is likely to be closely scrutinized, public health experts said. Approval will not only pivot on the strength of the trial data, but on whether Pfizer shows it can properly produce a pediatric version of the vaccine.

About a third of parents of children in that age group said they would wait and see before getting their children a shot, a recent Kaiser Family Foundation poll found.

Public discussion is crucial because many parents are torn between the fear of COVID-19 and concerns about vaccine side effects, Dr. Walt Orenstein, an epidemiologist at Emory University and a former director of the U.S. immunization program, told the Times.

If parents were less worried about the risks of coronavirus infection, safety would be their top priority, but if they were more worried, the vaccine's effectiveness would take priority, Orenstein said.

As with other vaccines, pediatricians would play a vital role in reducing parents' anxiety about their children receiving a COVID-19 vaccine, Orenstein noted.

The 2,268 children in Pfizer's study submitted to the FDA was a noticeably small number, Norman Baylor, former director of the FDA's vaccines office, said during a virtual panel on COVID-19 last week, the Times reported.

The company's adult trial included about 44,000 participants.

"It does beg the question of the size, given what we have for the adults: Would one expect more for the pediatric population?" Baylor said. "They may be thinking, 'Well, we know the vaccine is safe, because look at how many people we had in the adults.' But as we know, things may shift in that pediatric population."

More information

Visit the U.S. and Food and Drug Administration for more on COVID vaccines.

SOURCE: New York Times




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net